Join
Live feed
·
PRReleasevia Quantisnow
Beam Therapeutics Inc. logo

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

ByQuantisnow·Wall Street's wire, on your screen.
BEAM· Beam Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BEAM (Beam Therapeutics Inc.) and more on Quantisnow.